Table 5.
Baseline characteristics of the busulfan/cyclophosphamide cohort
| Characteristics | Sirolimus | No sirolimus | P |
|---|---|---|---|
| N | 13 | 26 | |
| Median age, y (range) | 50 (11-57) | 45 (23-56) | .28 |
| Sex, female | 7 (54) | 13 (50) | >.99 |
| Cell source | |||
| Peripheral blood stem cells | 11 (85) | 22 (82) | >.99 |
| Bone marrow | 2 (15) | 4 (18) | |
| HLA matching | |||
| Matched-related | 9 (69) | 15 (58) | .89 |
| Matched-unrelated | 3 (23) | 7 (27) | |
| Mismatched | 1 (8) | 4 (15) | |
| Multiple transplantations | 0 (0) | 9 (41) | .02 |
| Year of transplantation 2002 or later | 13 (100) | 21 (81) | .15 |
| Disease | |||
| AML | 8 (62) | 15 (58) | |
| ALL | 0 (0) | 4 (15) | |
| CLL/SLL/PLL | 1 (8) | 0 (0) | |
| MDS | 1 (8) | 3 (12) | |
| NHL | 1 (8) | 4 (15) | |
| Aplastic anemia | 2 (15) | 0 (0) | |
| Transplantation risk, low | 11 (85) | 18 (69) | .45 |
| Acute GVHD (grade II-IV) | 3 (23) | 7 (27) | >.99 |
AML indicates acute myeloid leukemia; ALL, acute lymphoblastic leukemia; CLL, chronic lymphocytic leukemia; SLL, small lymphocytic lymphoma; PLL, prolymphocytic leukemia; MDS, myelodysplastic disorder; and NHL, non-Hodgkin lymphoma.